These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23850479)

  • 1. Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers.
    Benzekry S; Hahnfeldt P
    J Theor Biol; 2013 Oct; 335():235-44. PubMed ID: 23850479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic therapy: chemotherapy revisited.
    Noronha V; Krishna MV; Patil V; Joshi A; Banavali SD; Prabhash K
    Indian J Cancer; 2013; 50(2):142-8. PubMed ID: 23979206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mathematical model to study low-dose metronomic scheduling for chemotherapy.
    Arora G; Bairagi N; Chatterjee S
    Math Biosci; 2024 Jun; 372():109186. PubMed ID: 38580078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic chemotherapy and nanocarrier platforms.
    Abu Lila AS; Ishida T
    Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.
    Kareva I; Waxman DJ; Lakka Klement G
    Cancer Lett; 2015 Mar; 358(2):100-106. PubMed ID: 25541061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
    Qiu H; Wang GM
    Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic chemotherapy: A relook at its basis and rationale.
    Rajasekaran T; Ng QS; Tan DS; Lim WT; Ang MK; Toh CK; Chowbay B; Kanesvaran R; Tan EH
    Cancer Lett; 2017 Mar; 388():328-333. PubMed ID: 28003122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomics chemotherapy: time for computational decision support.
    Barbolosi D; Ciccolini J; Meille C; Elharrar X; Faivre C; Lacarelle B; André N; Barlesi F
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):647-52. PubMed ID: 25082520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
    Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
    J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis and chemotherapy resistance: optimizing chemotherapy scheduling using mathematical modeling.
    Bodzioch M; Bajger P; Foryś U
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2281-2299. PubMed ID: 34050795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors.
    Launay S; Sabatier R; Brunelle S; Esterni B; Tarpin C; Viret F; Gravis G; Cappiello M; Provansal M; Extra JM; Bertucci F; Viens P; Goncalves A
    Anticancer Res; 2016 Jan; 36(1):293-9. PubMed ID: 26722056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing Chemotherapeutic Anti-cancer Treatment and the Tumor Microenvironment: An Analysis of Mathematical Models.
    Ledzewicz U; Schaettler H
    Adv Exp Med Biol; 2016; 936():209-223. PubMed ID: 27739050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic chemotherapy for cancer treatment: a decade of clinical studies.
    Romiti A; Cox MC; Sarcina I; Di Rocco R; D'Antonio C; Barucca V; Marchetti P
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):13-33. PubMed ID: 23475105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation.
    Biziota E; Mavroeidis L; Hatzimichael E; Pappas P
    Cancer Lett; 2017 Aug; 400():243-251. PubMed ID: 28017892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
    Benzekry S; Pasquier E; Barbolosi D; Lacarelle B; Barlési F; André N; Ciccolini J
    Semin Cancer Biol; 2015 Dec; 35():53-61. PubMed ID: 26361213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
    Jedeszko C; Paez-Ribes M; Di Desidero T; Man S; Lee CR; Xu P; Bjarnason GA; Bocci G; Kerbel RS
    Sci Transl Med; 2015 Apr; 7(282):282ra50. PubMed ID: 25855496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies.
    West J; Newton PK
    Cancer Res; 2017 Dec; 77(23):6717-6728. PubMed ID: 28986381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics and control of a mathematical model for metronomic chemotherapy.
    Ledzewicz U; Amini B; Schättler H
    Math Biosci Eng; 2015 Dec; 12(6):1257-75. PubMed ID: 26775862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.